Article info
PDFColon
Original research
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
- Correspondence to Professor Giorgio Stassi, Department of Surgical, Oncological and Stomatological Sciences, Università degli Studi di Palermo, Palermo, Italy; giorgio.stassi{at}unipa.it; Professor Ruggero De Maria, Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy; ruggero.demaria{at}unicatt.it
Citation
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
Publication history
- Received November 8, 2020
- Revised December 15, 2020
- Accepted December 18, 2020
- First published January 12, 2021.
Online issue publication
February 02, 2022
Article Versions
- Previous version (2 February 2022).
- Previous version (2 February 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.